02 March 2021: Clinical Research
The Role of Human Leukocyte Antigen-DR in Regulatory T Cells in Patients with Virus-Induced Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Lin Zhang AE , Xiuhong Nie AE* , Zhiming Luo BC , Bing Wei D , Guojie Teng FDOI: 10.12659/MSM.928051
Med Sci Monit 2021; 27:e928051
Table 3 Flow cytometry analysis of levels of T cell subsets in exacerbation groups, the stable chronic obstructive pulmonary disease (COPD) group, and the healthy smoking group.
| Health smokers (n=20) | Stable COPD (n=20) | Virus AECOPD (n=32) | Non-virus AECOPD (n=31) | P | ||
|---|---|---|---|---|---|---|
| CD3+ | 1336±362 | 1130±333 | 598±320 | 692±510 | 0.001 | |
| GOLD II | 1071±354 | 768±272 | 815±473 | |||
| GOLD III–IV | 1180±339 | 471±325 | 610±561 | |||
| CD4+ | 764±253 | 688±243 | 324±173 | 400±290 | 0.001 | |
| GOLD II | 733±243 | 400±153 | 463±297 | |||
| GOLD III–IV | 658±261 | 267±184 | 357±306 | |||
| CD4+Naive | 149 (99–184) | 126 (72–163) | 65 (28–82) | 95 (29–182) | 0.095 | |
| GOLD II | 115 (49–150) | 60 (28–80) | 95 (34–192) | |||
| GOLD III–IV | 129 (91–182) | 47 (11–72) | 92 (24–188) | |||
| CD4+Tcm | 281 (246–411) | 284 (237–393) | 156 (74–211) | 112 (50–295) | 0.004 | |
| GOLD II | 340 (263–396) | 156 (65–203) | 206 (102–293) | |||
| GOLD III–IV | 255 (210–335) | 120 (29–200) | 77 (41–313) | |||
| CD4+Tem | 223 (177–316) | 264 (170–353) | 105 (72–164) | 66 (51–162) | 0.010 | |
| GOLD II | 268 (170–435) | 104 (70–154) | 99 (65–233) | |||
| GOLD III–IV | 260 (160–370) | 91 (46–168) | 56 (36–146) | |||
| CD4+End | 28 (17–59) | 40 (22–70) | 7 (2–10) | 12 (2–24) | 0.021 | |
| GOLD II | 41 (19–61) | 5 (1–10) | 13 (4–56) | |||
| GOLD III–IV | 39 (26–90) | 7 (2–9) | 11 (2–24) | |||
| CD4+HLA-DR+ | 10 (8–17) | 12 (8–18) | 8 (3–11) | 18 (5–30) | 0.456 | |
| GOLD II | 14 (9–17) | 9 (5–11) | 27 (10–34) | |||
| GOLD III–IV | 9 (3–20) | 6 (2–10) | 10 (4–29) | |||
| CD4+Treg | 42 (32–58) | 31 (22–46) | 42 (11–75) | 37 (28–95) | 0.391 | |
| GOLD II | 33 (25–50) | 39 (25–72) | 49 (27–117) | |||
| GOLD III–IV | 23 (18–45) | 26 (7–76) | 34 (25–94) | |||
| CD4+Treg-HLA-DR+ | 6 (4–15) | 8 (4–11) | 5 (2–7) | 10 (3–25) | 0.224 | |
| GOLD II | 9 (5–16) | 5 (2–8) | 14 (4–23) | |||
| GOLD III–IV | 6 (2–10) | 3 (0.8–7) | 8 (3–30) | |||
| CD4+Treg-HLA-DR− | 33 (27–41) | 22 (17–36) | 37 (9–66) | 28 (19–62) | 0.880 | |
| GOLD II | 21 (17–39) | 31 (8–65) | 31 (22–98) | |||
| GOLD III–IV | 23 (10–34) | 23 (6–66) | 28 (10–60) | |||
| CD8+ | 412±163 | 406±130 | 232±157 | 187±137 | 0.002 | |
| GOLD II | 425±113 | 309±90 | 238±122 | |||
| GOLD III–IV | 390±150 | 173±183 | 152±145 | |||
| CD8+Naive | 31 (25–41) | 35 (15–60) | 28 (3–41) | 16 (7–55) | 0.773 | |
| GOLD II | 43 (13–72) | 29 (3–49) | 32 (14–71) | |||
| GOLD III–IV | 27 (18–54) | 25 (1–38) | 11 (4–58) | |||
| CD8+Tcm | 45±27 | 43±23 | 34±22 | 27±23 | 0.495 | |
| GOLD II | 38±26 | 50±6 | 39±22 | |||
| GOLD III–IV | 45±19 | 22±21 | 18±20 | |||
| CD8+Tem | 163 (105–214) | 140 (113–201) | 88 (44–112) | 55 (22–110) | 0.001 | |
| GOLD II | 142 (90–261) | 86 (40–97) | 56 (43–112) | |||
| GOLD III–IV | 140 (116–190) | 46 (28–210) | 54 (21–69) | |||
| CD8+End | 140 (86–219) | 121 (66–211) | 28 (19–145) | 38 (16–89) | 0.021 | |
| GOLD II | 114 (60–204) | 25 (18–140) | 59 (27–127) | |||
| GOLD III–IV | 133 (70–215) | 23 (16–79) | 21 (10–95) | |||
| CD8+HLA-DR+ | 5.2 (3.1–7.3) | 4.8 (2.5–8.0) | 3.7 (1.1–8.9) | 2.5 (1.2–3.9) | 0.335 | |
| GOLD II | 6.6 (2.9–8.3) | 4.1 (1.2–8.2) | 3.0 (1.7–4.8) | |||
| GOLD III–IV | 5.0 (2.5–5.0) | 2.2 (0.6–9.3) | 1.9 (0.6–3.7) |